Tumor Markers
Tumor Markers - Related Videos
03:19
Transduction to Label PDX Tumor Cells: Introducing Lentivirus Expressing Fluorescent Marker into the Tumor Cell In Vitro
0 Views •
2023
The following video describes a technique of transduction to label (patient-derived xenografts) PDX tumor cells, which is used for introducing lentivirus expressing green-fluorescent protein and luciferase reporters into the tumor cell in vitro.
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
0 Views •
Cited by 23 •
2014
An example of a nano drug based on polymalic acid is presented towards the rational design of personalized medicine that is applicable to cancer. It describes the synthesis of a nano drug to treat Her2-positive human breast cancer in a nude mouse.
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
0 Views •
Cited by 15 •
2015
This protocol describes a method for the detailed evaluation of leukocyte subsets within the tumor microenvironment in a mouse tumor model. Chemerin-expressing B16 melanoma cells were implanted subcutaneously into syngeneic mice. Cells from the tumor microenvironment were then stained and analyzed by flow cytometry, allowing for detailed leukocyte subset analyses.
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
0 Views •
Cited by 8 •
2017
This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.
FAQs
A single tumor-marker result may indicate biological activity associated with malignancy, but it does not establish that cancer is present. Some markers arise from the body’s response rather than directly from tumor cells, and many lack sufficient specificity for screening or diagnosis. Clinicians therefore interpret results alongside imaging, biopsy, and other diagnostic evidence before making clinical decisions.
Tumor markers can provide information about a tumor’s biological behavior because their levels may reflect molecules produced by malignant cells or changes in the body caused by the disease. This distinction matters clinically: a measurement may offer insight into disease activity without directly identifying every tumor cell. Interpretation depends on the broader clinical context and complementary test findings.
Trends can be more informative than an isolated measurement. Repeated tumor-marker testing allows clinicians to track changes during care and evaluate whether results are consistent with treatment response or suggest possible recurrence. These measurements do not replace imaging or biopsy, but their direction over time can contribute to assessing outcomes and deciding whether further evaluation is needed.
Laboratory assays can measure tumor markers in blood, urine, tissue, or other body fluids, so the specimen depends on the marker and clinical question. The resulting value must be interpreted as a laboratory measurement rather than a diagnosis by itself. Using the appropriate assay and considering results with other diagnostic methods helps clinicians evaluate cancer-related information more responsibly.
Clinicians first interpret a marker result in relation to the patient’s overall assessment, then compare it with imaging, biopsy, and other diagnostic findings. When monitoring is appropriate, measurements may be repeated to identify meaningful changes rather than relying on one value. This integrated approach helps distinguish supportive evidence from information that requires confirmation through other methods.
Their greatest clinical value often comes after cancer has been identified or treatment has begun. Tumor markers can support prognosis, help monitor treatment response, and indicate possible disease recurrence when interpreted with other evidence. These uses allow clinicians to evaluate outcomes and may help tailor care, while avoiding reliance on markers alone for screening or diagnosis.